Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by thisisriskystufon Jul 31, 2018 2:35pm

242 Views

Post# 28393034

Consensus Rating for TH is STRONG BUY

Current Target Price TMX High Target Price Estimate $19.50 Low Target Price Estimate $10.00 Mean Target Price Estimate $14.65 Date of Most Recent Estimate 07/23/18 TD Consensus Rating for TH is STRONG BUY ON TD 4 ANALYSTS HIGH $20 MEAN $17 LOW $14

Bullboard Posts

Full Circle Lithium goes global with its battery fire-fighter